×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: FDA | rare | blood | cancer | leukemia | Pfizer

Drug for Rare Blood Cancer OK'd

Drug for Rare Blood Cancer OK'd
(Copyright Fotolia)

Friday, 18 August 2017 08:49 AM

The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's treatment for a rare type of blood cancer.

The treatment, Besponsa, carries a boxed warning, the agency's severest form of warning reserved to caution against the most serious adverse events.

Besponsa was approved to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a disease that will affect about 5,970 people in the United States this year and kill about 1,440, according to the National Cancer Institute.

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell.

© 2022 Thomson/Reuters. All rights reserved.


Health-News
The U.S. Food and Drug Administration (FDA) said on Thursday it approved Pfizer Inc's treatment for a rare type of blood cancer.The treatment, Besponsa, carries a boxed warning, the agency's severest form of warning reserved to caution against the most serious adverse...
FDA, rare, blood, cancer, leukemia, Pfizer
111
2017-49-18
Friday, 18 August 2017 08:49 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
Find Your Condition
Get Newsmax Text Alerts
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved